GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAREPTA THERAPEUTICS INC

Explicit Guidance:

• No explicit quantitative financial guidance (revenue, earnings, margins, capex, or cash flow) provided for FY2025 or FY2026; however, management forecasts FY2027 as a "transformational year" driven by three high-value programs reaching key milestones.

Business-Segment Outlook:

• Exon Skipping (Duchenne): Anticipates competitive launches, specifically a DYN program targeting exon 51, potentially receiving PDUFA approval "next year" (FY2026); expects retention of the stable, home-dosed patient base (90% adherence) due to long-term safety data and established safety profile despite competition.
• Levitas (Duchenne): Establishes Q3 as a "clean baseline" for patient starts following the completion of a six-month commercial journey from start to dosing; projects long-term growth potential contingent on physician adoption of new data (Embark 3-year data, imaging data) and the upcoming Cohort 8 readout before specific timing can be predicted.
• DM1 (Myotonic Dystrophy Type 1): Phase 1b data readout expected "later this year"; aims to demonstrate DMPK knockdown and splicing correction substantially higher than the 10–25% range achieved by competitors, targeting "very meaningful doses" up to 8 mg/kg siRNA without dose-limiting toxicity.
• FSHD (Facioscapulohumeral Dystrophy): Aims to achieve >70% inhibition of Dux4-regulated genes in upcoming multiple-dose studies, setting a target significantly above the competitor benchmark of 50% (biopsy) or 20–30% (circulating biomarkers).
• Huntington's Disease: Expects "proof of biologic activity" data mid-next year (approx. May 2026), contingent on identifying the specific dose cohort that best illustrates CNS penetration and protein knockdown.

Market and Competitive Outlook:

• Competitive Landscape: Views DYN's potential approval as a challenge for the exon 51 market, but expects Serapta to retain stability among existing patients due to a decade-long safety track record and real-world evidence (reduced decline in pulmonary/cardiac function).
• Market Share Dynamics: Plans to compete for new incident patients on product attributes (safety, long-term data) while relying on high stickiness for the stable patient base; anticipates that switching decisions will be driven by patient/physician experience with current therapy stability rather than physician visit frequency.
• Delivery Advantage: Differentiates from competitors (e.g., Novartis, Al-Alam) by claiming superior systemic delivery and blood-brain barrier crossing capability for Huntington's, arguing against the limitations of bispecific antibodies or intrathecal delivery observed in other programs.
• Regulatory Standards: Anticipates the FDA will continue to require randomized controlled data for gene therapies demonstrating clinical benefit, particularly where microdystrophin expression does not guarantee clinical outcome; believes accelerated approval is viable for DM1, FSHD, and Huntington's based on robust biomarker data (splicing correction, Dux4 inhibition, CSF knockdown).

Macro / Industry Outlook:

• Regulatory Environment: Expects the FDA to maintain a high bar for clinical benefit proof in neuromuscular diseases, requiring robust safety databases and randomized data prior to approval, though accelerated pathways remain open for conditions with limited options and strong biomarker correlations.
• Pricing/Reimbursement: Notes existing robust access groups and reimbursement pathways are critical to maintaining patient adherence and home-dosing rates; no specific pricing changes or tariff impacts discussed.

Strategic Initiatives:

• Pipeline Expansion: Targeting registration studies for DM1 and FSHD with the goal of accelerated approval "not too far out" on the horizon.
• Milestone Timeline: By mid-next year, expects to have three transformational programs (FSHD, DM1, Huntington's) reaching proof-of-concept or registration-readiness, significantly altering the company's valuation profile.
• Dose Escalation: Plans to escalate doses in DM1 (up to 8 mg/kg) and Huntington's programs to maximize knockdown efficiency without toxicity, leveraging a unique alpha-B-beta-6 peptide ligand delivery vehicle.
• Long-term Vision: Aims to expand presence in neuromuscular and neurologic conditions beyond current pipeline, utilizing pre-clinical assets.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Accelerated approval pathways for DM1, FSHD, and Huntington's are contingent on generating specific biomarker thresholds (e.g., >70% Dux4 inhibition, robust splicing correction); FDA may require confirmatory randomized studies for FSHD.
• Competitive Dynamics: Future revenue could be impacted by the specifics of the DYN product label and its PDUFA outcome in the exon 51 market.
• Clinical Data Variability: Functional endpoints (e.g., 6MWT, VHOT) in small Phase 1b populations are not statistically powered to show immediate clinical benefit; reliance on surrogate biomarkers carries execution risk.
• Timeline Delays: Huntington's timeline has been adjusted to "middle of next year" due to the need to identify the most illustrative dose cohort for proof of biology.

Management Tone on the Future:

• Confidence Level: High confidence in the durability of the Duchenne cash business and the transformative potential of the sRNA pipeline; describes the current setup as "unique" and "very favorable."
• Strategic Shift: Expresses strong belief in the ability to fund future growth via cash flows from the commercial business without requiring equity raises.
• Comparative Outlook: Contrasts Serapta's position favorably against competitors (Novartis, Al-Alam), citing superior delivery mechanisms and cleaner safety profiles as key differentiators.
• Caveats: Repeatedly cautions against over-indexing on small-sample functional data; emphasizes waiting for larger, longer-term trends before making definitive long-term predictions on Levitas growth rates.

Miscellaneous:

• Safety Profile: Highlights extensive safety exposure database (>1,200 ambulatory patients dosed) compared to the smaller exposure histories of single-arm competitor studies.
• Biomarker Strategy: Focuses on "causal biology" (DMPK knockdown, splicing correction, Dux4 inhibition) as the primary validation metrics rather than immediate functional improvements in Phase 1b.
• Home-Dosing: Emphasizes that 90% of patients participate in home-dosing, creating a high barrier to switching and ensuring adherence.